CorMedix Inc. reported second quarter 2026 financial results with consolidated revenue of $101.9 million and net income of $26.0 million, or $0.33 basic and $0.29 diluted EPS. Revenue comprised $66.1 million from DefenCath sales and $35.8 million from the acquired Melinta portfolio. The company raised its full-year 2026 adjusted EBITDA guidance to a range of $125 to $140 million while maintaining revenue guidance of $325 to $345 million. CorMedix also announced an anticipated FDA submission for a supplemental New Drug Application for REZZAYO in the third quarter and signed a new multi-year supply agreement with a large dialysis operator. The company operates in the biopharmaceutical industry, developing and commercializing therapeutic products for institutional care settings.

CorMedix Inc. announced that the U.S. District Court for the District of New Jersey granted preliminary approval of a proposed settlement resolving consolidated shareholder derivative lawsuits alleging breach of fiduciary duties and misleading statements regarding FDA approval delays for DefenCath during the relevant period from October 2019 to August 2022. The settlement requires CorMedix to implement corporate governance reforms, including establishing a disclosure committee and enhancing the Nominating and Governance Committee's oversight role, which must be maintained for at least three and a half years. Plaintiffs' counsel may petition the court for attorneys' fees and expenses not exceeding $3,900,000, payable by CorMedix upon final approval. A final settlement hearing is scheduled for September 23, 2026. CorMedix Inc. operates in the biopharmaceutical industry, focusing on developing and commercializing therapeutic products for life-threatening diseases.

On June 29, 2026, CorMedix Inc. restructured its executive leadership. Elizabeth Hurlburt, previously the Chief Operating Officer, was appointed to the new role of Chief Operating and Commercial Officer, gaining oversight of commercial functions, medical affairs, regulatory, and clinical operations. Concurrently, Michael Seckler departed the company. CorMedix is a biopharmaceutical company that develops and commercializes therapeutic products.

CorMedix Inc. dismissed CBIZ CPAs P.C. and appointed Ernst & Young LLP (EY) as its new independent registered public accounting firm for the fiscal year ending December 31, 2026. The dismissal follows a previously reported material weakness in internal control over financial reporting related to the review of significant, non-routine transactions. CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing products for cell-based therapies.

At its 2026 Annual Meeting of Stockholders on June 23, 2026, CorMedix Inc. elected seven directors, approved executive compensation for 2025, and ratified the appointment of CBIZ CPAs P.C. as its independent auditor. Notably, stockholders failed to approve five separate proposals: the ratification of Certificate of Designation Amendments, technical changes to the amended and restated Charter, an amendment to allow class voting for preferred stock terms, the designation of exclusive forums for legal claims, and the updating of officer liability provisions under Delaware law. The company is a biopharmaceutical company that develops and commercializes products for the treatment of serious diseases.

CorMedix, Inc. announced via press release on June 8, 2026, that the U.S. Court of Appeals for the Federal Circuit affirmed a district court judgment that Nexus Pharmaceuticals Inc.'s generic minocycline product infringed two of the Company's patents. The decision rejected Nexus's invalidity challenge against the patent infringement.